United Therapeutics Corporation (NASDAQ:UTHR) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET
Company Participants
Dewey Steadman - Head of Investor Relations
Martine Rothblatt - Chairperson & Chief Executive Officer
Michael Benkowitz - President & Chief Operating Officer
James Edgemond - Chief Financial Officer & Treasurer
Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation
Conference Call Participants
Roanna Ruiz - Leerink Partners
Jessica Fye - JPMorgan
Ash Verma - UBS
Joseph Thome - TD Cowen
Andreas Argyrides – Oppenheimer
Operator
Good morning, everyone and welcome to the United Therapeutics Corporation Second Quarter 2024 Earnings Webcast. My name is Cole and I will be your conference operator today. All participants on the call portion of this webcast will be in listen-only mode until the question-and-answer portion of the earnings call. [Operator Instructions] And please note this call is being recorded.
I would now like to turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics. Please go ahead.
Dewey Steadman
Yes. Thank you, Cole. Good morning. It's my pleasure to welcome you to the United Therapeutics Corporation's second quarter 2024 earnings webcast. Remarks we make today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements will involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements.
Remarks today may discuss the progress and results of clinical trials or other developments with respect to our products and these remarks are intended solely to educate investors and are not intended to serve as the basics for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. And full prescribing information for the products are available on our website.
Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Dr. Leigh Peterson, our Executive Vice President, Product Development and Xenotransplantation and Pat Poisson, our Executive Vice President of Technical Operations.
Note that Michael Benkowitz and I will participate in a fireside chat and one-on-one meetings at the Morgan Stanley 22nd Annual and Global Healthcare Conference in New York on September 4, and James Edgemond and I will participate in a fireside chat and one-on-one meetings at the 2024 Wells Fargo Health Care Conference in Boston the next day, September 5.